China Universal Asset Management Co., Ltd. Halozyme Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$1.03 Billion
Q2 2025

A detailed history of China Universal Asset Management Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 24,748 shares of HALO stock, worth $1.71 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

24,748

Previous 24,702 0.19%

Holding current value

$1.71 Million

Previous $1.58 Million 18.34%

% of portfolio

0.12%

Previous 0.15%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 28, 2025	BUY	$47.91 - $70.14 $2,203 - $3,226	46 Added 0.19%	24,748 $1.29 Million
Q1 2025 Apr 29, 2025	SELL	$47.74 - $65.16 $108,608 - $148,239	-2,275 Reduced 8.43%	24,702 $1.58 Million
Q4 2024 Jan 23, 2025	BUY	$42.57 - $61.09 $111,235 - $159,628	2,613 Added 10.72%	26,977 $1.29 Million
Q3 2024 Oct 25, 2024	BUY	$51.3 - $64.42 $482,784 - $606,256	9,411 Added 62.94%	24,364 $1.39 Million
Q2 2024 Jul 19, 2024	SELL	$37.81 - $52.4 $355,224 - $492,298	-9,395 Reduced 38.59%	14,953 $782,000
Q1 2024 Apr 29, 2024	SELL	$33.68 - $41.95 $1 Million - $1.25 Million	-29,733 Reduced 54.98%	24,348 $990,000
Q4 2023 May 21, 2024	BUY	$33.32 - $42.1 $990,703 - $1.25 Million	29,733 Added 122.12%	54,081 $2 Million
Q4 2023 Jan 23, 2024	SELL	$33.32 - $42.1 $172,031 - $217,362	-5,163 Reduced 8.71%	54,081 $2 Million
Q3 2023 May 21, 2024	BUY	$36.46 - $44.03 $406,091 - $490,406	11,138 Added 23.15%	59,244 $2.26 Million
Q3 2023 Oct 30, 2023	BUY	$36.46 - $44.03 $406,091 - $490,406	11,138 Added 23.15%	59,244 $2.26 Million
Q2 2023 May 21, 2024	BUY	$30.28 - $38.74 $1.15 Million - $1.48 Million	38,094 Added 380.48%	48,106 $1.74 Million
Q2 2023 Jul 27, 2023	BUY	$30.28 - $38.74 $1.15 Million - $1.48 Million	38,094 Added 380.48%	48,106 $1.74 Million
Q1 2023 May 21, 2024	SELL	$32.86 - $55.7 $381,964 - $647,456	-11,624 Reduced 53.73%	10,012 $382,000
Q1 2023 Apr 27, 2023	SELL	$32.86 - $55.7 $381,964 - $647,456	-11,624 Reduced 53.73%	10,012 $382,000
Q4 2022 May 21, 2024	SELL	$40.06 - $59.44 $108,642 - $161,201	-2,712 Reduced 11.14%	21,636 $1.23 Million
Q4 2022 Jan 31, 2023	SELL	$40.06 - $59.44 $132,198 - $196,152	-3,300 Reduced 13.23%	21,636 $1.23 Million
Q3 2022 Oct 21, 2022	BUY	$38.53 - $51.78 $960,784 - $1.29 Million	24,936 New	24,936 $986,000

Others Institutions Holding HALO

# of Institutions

605

Shares Held

127M

Call Options Held

408K

Put Options Held

388K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.61B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account

China Universal Asset Management Co., Ltd. Halozyme Therapeutics, Inc. Transaction History